New

North America Neoantigens Market

2021

North America Neoantigens Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Combination Therapy and Mono Therapy) and Therapeutic Specialty (Gastrointestinal Cancer, Lung Cancer, Solid Tumor, Urinary Systems Cancers, Melanoma, Head and Neck Cancer, and Others)

Publication Month: Nov 2021 | Report Code: TIPRE00025573 | No. of Pages: 68 | Category: Pharmaceuticals | Status: Published

Market Insights

North America Neoantigens Market to Grow at a CAGR of 31.5% to reach US$ 501,23 Million from 2021 to 2028

Covid
Assesing the covid-19 impact?
Get the Latest COVID-19 Analysis on this market
Request Now
Happy to join you in your fight against the COVID-19 economic pandemic!

The neoantigens market in North America is expected to grow from US$ 127.56 Million in 2023 to US$ 501.23 Million by 2028; it is estimated to grow at a CAGR of 31.5% from 2023 to 2028.


The US, Canada, and Mexico are major economies in North America. Application of next-generation sequencing for neoantigen identification is the major factor driving the growth of the North America neoantigens market. Advancements in biotechnology have enabled the use of next-generation sequencing (NGS) techniques for various diagnostic and therapeutic applications. Discoveries related to neoantigens have allowed the development of personalized therapies for cancers that are still in the adoption phases. However, there are broader opportunities in the field of neoantigens and immuno-oncology that are yet unmet. Developments in the healthcare information technologies (IT) has allowed various inventions with feasible options that ease research and developments in the field of cancer. Companies operating in the cancer-related healthcare IT segment are offering solutions and software that are supported by the machine-learning; these offerings help in predicting neoantigens based on NGS data for personalized cancer treatment. These developments are encouraging the application of NGS in immune-oncology research, as well as in neoantigen identification, which is emerging as a lucrative opportunity for neoantigen market players. Further, the NGS is expected to simplify the process of identifying neoantigens as potential biosimilars or synthetic therapeutic agents, as a part of the treatment or immunotherapy for cancer in the coming years, which is further anticipated to drive the market in North America.

The impacts of COVID-19 pandemic are being felt across several markets in North America. Although the healthcare sector had witnessed SARS, H1N1, and other outbreaks in the last few years, the severity of the COVID-19 has made the situation more complicated due to its mode of transmission. North America has been witnessing growing number of COVID-19 cases since its outbreak. For instance, according to WHO, from January 3, 2020 to May 5, 2021, there have been 32,123,136 confirmed cases of COVID-19 with 572,190 deaths. The cases are also increasing in Mexico and Canada. In Mexico, the cases have reached to 2,355,985 with 218,007 deaths. Similarly, in Canada, there are about 1,257,328 COVID-19 cases, with 24,450 deaths reported so far. In the US, many doctors, hospitals, and other healthcare facilities are delaying or canceling the cancer procedures, surgeries, and sometimes screenings or other treatments, if it is not considered urgent, emergency, or life-threatening condition. Due to weak immune system, cancer patients are requested to follow social distancing norms as they are more prone to get infected with virus that causes COVID-19. More research is being conducted on COVID-19 vaccines other than any other disease vaccine. For instance, a research study on “Cancer therapy tool informs COVID-19 vaccines” was published on April 2020 in Icahn School of Medicine at Mount Sinai, New York, NY, USA. In this study, a computational tool was designed to predict candidate neoantigens for cancer vaccines, which helps in the formation of T-cell vaccines against SARS-CoV-2. Pharmaceutical companies are halting ongoing studies and delaying the launch of new trials. Therefore, owing to these points, the pandemic is likely to affect cancer vaccine market.

Get more information on this report :



North America Neoantigens Market Segmentation

North America Neoantigens Market – By Treatment

  • Combination Therapy
  • Mono Therapy

North America Neoantigens Market – By Therapeutic Specialty

  • Gastrointestinal Cancer
  • Lung Cancer
  • Solid Tumors
  • Urinary System Cancers
  • Melanoma
  • Head and Neck Cancer
  • Others

North America Neoantigens Market– By Country

  • US
  • Canada
  • Mexico

North America Neoantigens Market-Companies Mentioned

  • Advaxis, Inc.
  • Gradalis, Inc.
  • Gritstone Oncology
  • Medigene AG
  • Moderna, Inc.
  • Ziopharm Oncology, Inc

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Neoantigens Market – By Treatment

1.3.2 North America Neoantigens Market – By Therapeutic Specialty

1.3.3 North America Neoantigens Market– By Country

2. North America Neoantigens Market – Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Neoantigens Market– Market Landscape

4.1 Overview

4.2 PEST Analysis

4.2.1 North America PEST Analysis

4.3 Expert Opinion

5. North America Neoantigens Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Developments in Neoantigen Vaccines Against Cancer

5.1.2 Increasing Prevalence of Cancer

5.2 Market Restraints

5.2.1 Possible Side Effects Associated with Neoantigen Vaccines

5.3 Market Opportunities

5.3.1 Application of Next-generation Sequencing for Neoantigen Identification

5.4 Future Trends

5.4.1 Use of AI in Neoantigen Vaccine Development

5.5 Impact Analysis

6. Neoantigens Market – North America Analysis

6.1 North America Neoantigens Market Revenue Forecast and Analysis

7. North America Neoantigens Market Analysis – By Treatment

7.1 Overview

7.2 North America Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

7.3 Combination Therapy

7.3.1 Overview

7.3.2 Combination Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

7.4 Mono Therapy

7.4.1 Overview

7.4.2 Mono Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8. North America Neoantigens Market Analysis – By Therapeutic Specialty

8.1 Overview

8.2 North America Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

8.3 Gastrointestinal Cancer

8.3.1 Overview

8.3.2 Gastrointestinal Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.4 Lung Cancer

8.4.1 Overview

8.4.2 Lung Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.5 Solid Tumors

8.5.1 Overview

8.5.2 Solid Tumors: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.6 Urinary System Cancers

8.6.1 Overview

8.6.2 Urinary System Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.7 Melanoma

8.7.1 Overview

8.7.2 Melanoma: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.8 Head and Neck Cancers

8.8.1 Overview

8.8.2 Head and Neck Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

8.9 Others

8.9.1 Overview

8.9.2 Others: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

9. North America Neoantigens Market – Country Analysis

9.1 North America: Neoantigens Market Revenue and Forecast to 2028

9.1.1 Overview

9.1.2 North America: Neoantigens Market, by Country, 2023 & 2028 (%)

9.1.3 US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.1 US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.3.2 US: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.3.3 US: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.1.4 Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.1 Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.4.2 Canada: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.4.3 Canada: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

9.1.5 Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.1 Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

9.1.5.2 Mexico: Neoantigens Market, by Treatment, 2023–2028 (USD Thousand)

9.1.5.3 Mexico: Neoantigens Market, by Therapeutic Specialty, 2023–2028 (USD Thousand)

10. Impact Of COVID-19 Pandemic on North America Neoantigens Market

10.1 North America: Impact Assessment of COVID-19 Pandemic

11. North America Neoantigens Market–Industry Landscape

12. Company Profiles

12.1 Advaxis, Inc.

12.1.1 Key Facts

12.1.2 Business Description

12.1.3 Products and Services

12.1.4 Financial Overview

12.1.5 SWOT Analysis

12.1.6 Key Developments

12.2 Gradalis, Inc.

12.2.1 Key Facts

12.2.2 Business Description

12.2.3 Products and Services

12.2.4 Financial Overview

12.2.5 SWOT Analysis

12.2.6 Key Developments

12.3 Gritstone Oncology

12.3.1 Key Facts

12.3.2 Business Description

12.3.3 Products and Services

12.3.4 Financial Overview

12.3.5 SWOT Analysis

12.3.6 Key Developments

12.4 Medigene AG

12.4.1 Key Facts

12.4.2 Business Description

12.4.3 Products and Services

12.4.4 Financial Overview

12.4.5 SWOT Analysis

12.4.6 Key Developments

12.5 Ziopharm Oncology, Inc.

12.5.1 Key Facts

12.5.2 Business Description

12.5.3 Products and Services

12.5.4 Financial Overview

12.5.5 SWOT Analysis

12.5.6 Key Developments

12.6 Moderna, Inc.

12.6.1 Key Facts

12.6.2 Business Description

12.6.3 Products and Services

12.6.4 Financial Overview

12.6.5 SWOT Analysis

12.6.6 Key Developments

13. Appendix

13.1 About the Insight Partners

13.2 Glossary of Terms

LIST OF TABLES

Table 1. New Cancer Cases Registered Worldwide, 2020

Table 2. North America Neoantigens Market – Revenue and Forecast to 2028 (US$ Thousand)

Table 3. US: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 4. US: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 5. Canada: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 6. Canada: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 7. Mexico: Neoantigens Market, by Treatment – Revenue and Forecast to 2028 (USD Thousand)

Table 8. Mexico: Neoantigens Market, by Therapeutic Specialty – Revenue and Forecast to 2028 (USD Thousand)

Table 9. Market Developments Done By Companies

Table 10. Glossary of Terms, Neoantigens Market

LIST OF FIGURES

Figure 1. North America Neoantigens Market Segmentation

Figure 2. North America Neoantigens Segmentation, By Country

Figure 3. North America Neoantigens Market Overview

Figure 4. Combination Therapy Segment Holds Largest Share of North America Neoantigens Market

Figure 5. US to Show Remarkable Growth During Forecast Period

Figure 6. North America: PEST Analysis

Figure 7. Expert Opinion

Figure 8. North America Neoantigens Market Impact Analysis of Drivers and Restraints

Figure 9. North America Neoantigens Market – Revenue Forecast and Analysis – 2023- 2028

Figure 10. North America Neoantigens Market Revenue Share, by Treatment (2023 and 2028)

Figure 11. Combination Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 12. Mono Therapy: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 13. North America Neoantigens Market Revenue Share, by Therapeutic Specialty (2023 and 2028)

Figure 14. Gastrointestinal Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 15. Lung Cancer: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 16. Solid Tumors: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 17. Urinary System Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 18. Melanoma: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 19. Head and Neck Cancers: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 20. Others: North America Neoantigens Market– Revenue and Forecast to 2028 (US$ Thousand)

Figure 21. North America: Neoantigens Market, by Key Country – Revenue (2023) (USD Thousand)

Figure 22. North America: Neoantigens Market, by Country, 2023 & 2028 (%)

Figure 23. US: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 24. Canada: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 25. Mexico: Neoantigens Market – Revenue and Forecast to 2028 (USD Thousand)

Figure 26. Impact of COVID-19 Pandemic in North American Country Markets

  1. Advaxis, Inc.
  2. Gradalis, Inc.
  3. Gritstone Oncology
  4. Medigene AG
  5. Moderna, Inc.
  6. Ziopharm Oncology, Inc
  • To understand the North America neoantigens market landscape and identify market segments that are most likely to guarantee a strong return
  • Stay ahead of the race by comprehending the ever-changing competitive landscape for North America neoantigens market
  • Efficiently plan M&A and partnership deals in North America neoantigens market by identifying market segments with the most promising probable sales
  • Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form North America neoantigens Market
  • Obtain market revenue forecast for market by various segments from 2021-2028 in North America region.
TIPRE00025573
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Pricing
Request for Sample
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.